Mesavancol (Mesalazine)

Mesalazine works by inhibiting cyclooxygenase and lipoxygenase pathways, lowering prostaglandin and leukotriene production. It also scavenges free radicals and modulates NF‑κB signaling, which together reduce inflammatory mediators and calm the intestinal immune response.

The specific dose of Mesavancol is determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Dosage regimens are individualized and should follow the healthcare professional’s instructions.

Safety data for mesalazine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mesavancol (mesalazine) belongs to the aminosalicylate class, which is often used as first‑line therapy for mild to moderate disease. Compared with systemic steroids or immunomodulators, mesalazine targets local intestinal inflammation with a generally favorable safety profile, though it may be less potent in severe cases.

Mesavancol should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, excessive heat, and direct sunlight to maintain its stability and potency.

Mesavancol is taken orally, usually as tablets or granules, as directed by the prescribing physician. The medication should be swallowed with water and taken with or without food according to the label instructions.

Serious risks include severe allergic reactions such as anaphylaxis, myocarditis, and blood dyscrasias like neutropenia or agranulocytosis. Patients should seek immediate medical attention if they experience symptoms such as difficulty breathing, chest pain, or unexplained bruising or infections.

Mesavancol should be avoided in individuals with known hypersensitivity to mesalazine or other aminosalicylates. Caution is also advised for patients with severe renal or hepatic impairment, and it should not be used without medical supervision in these populations.